BridgeBio Pharma Q4 Earnings Call Highlights

Core Insights - BridgeBio Pharma's Attruby has shown strong growth, particularly among first-line patients, attributed to exceptional clinical data and effective field execution [1][4] - The company is transitioning from a focus on R&D spending to becoming a multi-product business with expected revenue growth and cash generation [3][5] Financial Performance - For Q4 2025, BridgeBio reported net product revenue of $146 million, contributing to a total revenue of $502.1 million for the full year, up from $221.9 million in 2024 [2][15] - The company ended 2025 with $587.5 million in cash and issued $632.5 million in convertible notes in January 2026, extending its financial runway [5][17] - Operating costs for Q4 2025 were $293.7 million, with full-year costs reaching $1.0 billion, primarily due to increased SG&A expenses related to the Attruby launch [16][17] Product and Pipeline Developments - Attruby has achieved over 25% market share in the MBRX category as of December 31, 2025, with 7,804 unique prescriptions written by 1,856 prescribers [2][7] - The company reported positive Phase 3 results for several late-stage programs, including encaleret, BBP-418, and infigratinib, with infigratinib meeting its primary endpoint with a p-value of <0.0001 [6][11] - Upcoming product launches for encaleret and BBP-418 are anticipated in late 2026 or early 2027 [14] Intellectual Property and Market Position - BridgeBio's commercial strategy for Attruby is considered independent of the intellectual property status of tafamidis, with management emphasizing clinical performance over IP concerns [8][9] - The company maintains a base case assumption for generic entry in Europe by 2030, while asserting that Vyndamax should have protection into the 2030s [9] Strategic Outlook - Management expects to transition from being cash-consumptive to generating significant cash flows by 2028, with the pipeline projected to start generating cash by late 2027 [5][17] - The company is focused on reinvesting in R&D to exceed its cost of capital, while also considering other capital allocation options such as buybacks or dividends if necessary [19]